Emerging from the UK, retatrutide, a new compound , is sparking considerable interest within the healthcare community regarding its ability for body management . This dual GIP and GLP-1 target agonist seems to offer a significant benefit over established therapies, showing positive results in preliminary clinical assessments. Researchers believe it